WT1 and leukemia: The intracellular expression of these antigens may represent a limitation, but Rafiq et al. generated a CAR construct against WT1, thus demonstrating not only the possibility to extending CAR-T recognition beyond extracellular antigens, increasing the number of potential leukemia-specific targets, but also that these antigens can be harnessed for CAR-T cell therapy [111].